Trident Lifeline Limited has announced that its subsidiary Trident Mediquip Limited has completed a bonus share allotment to existing shareholders. The disclosure was made on February 2, 2026, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Bonus Share Allotment Details

Trident Mediquip Limited (CIN: U33309GJ2019PLC110421) allotted 9,34,160 new bonus shares to Trident Lifeline Limited. Despite receiving these additional shares, Trident Lifeline's percentage shareholding in its subsidiary remains unchanged at 60.04%.

Subsidiary Company Profile

Trident Mediquip Limited was incorporated on October 19, 2019, under the Companies Act, 2013, with its registered office in Surat, Gujarat. The company operates in the pharmaceuticals and chemical industry with a current turnover of 21.29 crore.

Capital Structure

Financial Performance

The subsidiary's turnover performance over the last three financial years shows:

Related Party Transaction

The transaction qualifies as a related party transaction since Trident Mediquip Limited is a subsidiary of Trident Lifeline Limited. Key promoters and directors including Mr. Amit Bhupendra Halvawala, Mr. Chetan Chandrakant Jariwala, and Mr. Hardik Jigishkumar Desai have interests in both entities. The company has confirmed that the transaction is being undertaken on an arm's length basis.

Regulatory Compliance

The disclosure was made in accordance with SEBI (LODR) Regulations, 2015, and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The announcement was signed by Nikita Sharma, Company Secretary and Compliance Officer (M. No.: A60595).

Trident Lifeline Limited has delivered robust financial performance in Q3FY26, demonstrating strong growth across all key operational metrics. The pharmaceutical company, which specializes in manufacturing and exporting pharmaceutical formulations, filed its earnings presentation under Regulation 30 on January 20, 2026.

Q3FY26 Financial Performance

The company's third quarter results showcase impressive year-on-year growth momentum. Revenue from operations reached ₹2,456.30 lakh, representing a substantial 44% increase compared to Q3FY25.

EBITDA margins remained healthy at 29%, showing improvement both sequentially and year-on-year. The company achieved EBITDA of ₹717.32 lakh, marking a 53% increase from the previous year.

Nine-Month Performance Highlights

The nine-month results for FY26 further reinforce the company's strong operational trajectory. Total revenue for 9MFY26 stood at ₹7,246.47 lakh, reflecting a robust 50% year-on-year growth.

Business Model and Global Presence

Trident Lifeline operates through a hybrid manufacturing model, combining its own facilities with contract manufacturing arrangements. The company maintains a formidable presence in export markets including African, Latin American, CIS and East Asian countries, with operations spanning 44 countries globally.

The company's product portfolio encompasses various therapeutic categories including anti-bacterial, anti-diabetic, anti-malarial, and multivitamin formulations. Product categories include tablets, capsules, syrups, ointments, and dental care products, with tablets and capsules accounting for 56% of revenue.

Strategic Growth Initiatives

The company has made significant investments in product registrations to bolster future growth. As of December 31, 2025, Trident Lifeline has 1,070 registered products across export markets, with an additional 2,458 product registrations currently in process. The company targets 300-400 additional product registrations annually as part of its expansion strategy.

Management Commentary

According to the management commentary, the outlook for the remaining year and coming periods remains strong. Business operations are projected to grow at both standalone and consolidated levels, driven by the company's strategic approach combining organic and inorganic expansion initiatives. The company continues to focus on molecules going off-patent in developed markets, which presents superior growth opportunities and potential for better profitability margins.